Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.50 |
| ▸ | GABRP | O00591 | 6/20 | 0.50 |
| ▸ | GABRD | O14764 | 6/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.50 |
| ▸ | GABRE | P78334 | 6/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31172628 | 1.00 | CYP1A2 (0.55) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL20267528 | 0.88 | ALDH1A1 (0.49) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL21241043 | 0.86 | POLB (0.44) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL229176 | 0.84 | CA12 (0.55) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL10003611 | 0.84 | CYP1A2 (0.53) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL1971939 | 0.84 | MAPK1 (0.61) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL29637478 | 0.84 | MAPK1 (0.61) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL29031128 | 0.82 | SMN1; SMN2 (0.47) | CYP1A2KDM4EALDH1A1MAPTNPC1 | |
| SCHEMBL1808295 | 0.82 | ALDH1A1 (0.55) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL347328 | 0.82 | CYP1A2 (0.51) | CYP1A2GABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208603-B2 | Reducing amination with cyanohydrin | PIERRE FABRE MEDICAMENT (FR) | 2007-04-24 | — | — | US | claimed |
| EP-1358179-B1 | SYNTHESIS METHOD AND INTERMEDIATES OF PYRIDIN-2-YL-METHYLAMINE | PF MEDICAMENT (FR) | 2006-05-10 | — | — | EP | claimed |
| US-20040116705-A1 | Reducing amination with cyanohydrin | PIERRE FABRE MEDICAMENT (FR) | 2004-06-17 | — | — | US | claimed |
| EP-1358179-A1 | SYNTHESIS METHOD AND INTERMEDIATES OF PYRIDIN-2-YL-METHYLAMINE | PIERRE FABRE MEDICAMENT (FR) | 2003-11-05 | — | — | EP | claimed |
| WO-2002064585-A1 | SYNTHESIS METHOD AND INTERMEDIATES OF PYRIDIN-2-YL-METHYLAMINE | PIERRE FABRE MEDICAMENT (FR) | 2002-08-22 | — | — | WO | claimed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20200290992-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | AUSPEX PHARMACEUTICALS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-10626105-B2 | Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds | AUSPEX PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| WO-2018057576-A1 | DEUTERIUM-SUBSTITUTED PYRIDIN- AND PYRIMIDIN-2-YL-METHYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20180079742-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | AUSPEX PHARMACEUTICALS, INC. | 2018-03-22 | — | — | US | disclosed |
| US-5717094-A | 6-THIOCHROMANYL-ETHYNE, 6-CHROMANYL ETHYNE AND 6-TETRAHYDROQUINOLINYL ETHYNE OR THEIR METAL SALTS ARE REACTED WITH SUITABLE HALO SUBSTITUTED PHENYL OR HETEROARYL COMPUNDS | ALLERGAN (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0719779-A1 | SUBSTITUTED THIAZOLO [3,2-ALPHA]AZEPINE DERIVATIVE | Eisai Co., Ltd. (JP) | 1996-07-03 | — | — | EP | disclosed |
| EP-0419132-B1 | Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity | ALLERGAN INC (US) | 1995-09-06 | — | — | EP | disclosed |
| US-5248777-A | Inhibitors of ornithine decarboxylase | ALLERGAN, INC. (US) | 1993-09-28 | — | — | US | disclosed |
| US-5053523-A | Chemical intermediate for compounds having retinoic acid-like activity | ALLERGAN, INC. (US) | 1991-10-01 | — | — | US | disclosed |
| US-5023341-A | Acetylene thiochroman | ALLERGAN, INC. (US) | 1991-06-11 | — | — | US | disclosed |
| EP-0419132-A2 | Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity | ALLERGAN, INC. (US) | 1991-03-27 | — | — | EP | disclosed |
| US-4923993-A | Process for the preparation of 2-pyridinecarboxylic acid derivatives and 1-amino-1,4-dihydropyridine-2-carboxylic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1990-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290992-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | HTR2C, HTR5A, HTR1A | CYP1A2 329/4885GABRA1 451/4885GABRG2 790/4885 |
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | CYP1A2 95/4885GABRA1 3024/4885GABRG2 3682/4885 |
| US-20180079742-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | HTR2C, HTR5A, HTR1A | CYP1A2 329/4885GABRA1 451/4885GABRG2 790/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | CYP1A2 935/4885GABRA1 2720/4885GABRG2 2096/4885 |
| US-10626105-B2 | Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds | HTR2C, HTR5A, HTR1A | CYP1A2 329/4885GABRA1 451/4885GABRG2 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.